Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot randomized, placebo-controlled, double-blind study - MASTRANDREA, Lucy; YU, Jihnhee; BEHRENS, Torsten; BUCHLIS, John; ALBINI, Christine; FOURTNER, Shannon; QUATTRIN, Teresa (Diabetes care, 2009)
Keywords: Adolescent; Biological and medical sciences; Blood; c-peptide; C-Peptide - metabolism; Cells; Child; Child, Preschool; children; Children & youth; Chronic illnesses; Complications and side effects; Diabetes; Diabetes. Impaired glucose tolerance; Disease; Dosage and administration; Double-Blind Method; drug effects; Drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etanercept; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Feasibility Studies; Female; Glycated Hemoglobin; Glycated Hemoglobin A - drug effects; Glycated Hemoglobin A - metabolism; Health aspects; Hospitalization; Hospitals; Humans; Hypoglycemic Agents; Hypoglycemic Agents - therapeutic use; Immunoglobulin G; Immunoglobulin G - therapeutic use; immunology; Immunosuppressive Agents; Immunosuppressive Agents - therapeutic use; Insulin; Insulin - metabolism; Insulin - therapeutic use; Insulin Secretion; insulin-dependent diabetes mellitus; Insulin-Secreting Cells; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Islets of Langerhans; Islets of Langerhans - immunology; leukocyte count; liver; Male; Medical sciences; Metabolic diseases; metabolism; Miscellaneous; Monoclonal antibodies; Original Research; Patient Selection; patients; Physical examinations; Physiological aspects; Pilot Projects; Placebos; Public health. Hygiene; Public health. Hygiene-occupational medicine; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor - therapeutic use; renal function; Rodents; secretion; therapeutic use; therapeutics; Type 1 diabetes; women; Womens health; United States; Endocrinopathy; Human; Immunopathology; Nutrition; Cytokine; Autoimmune disease; Metabolic diseases; Early stage; Anti-Tumor Necrosis Factor-alpha; Immunomodulator; Randomization; Treatment; Etanercept; Type 1 diabetes; Anticytokine; Double blind study; Antagonist; Fusion protein; Child; Tumor necrosis factor α; Endocrinology